Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases

<div>Mean sclerostin concentrations with standard error of the mean (SEM) in patients with BPH, prostate cancer without metastases (PC cM0), or prostate cancer with metastases (PC cM1).</div>

Disease Markers

fig3

Figure 3

Figure 3: Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases 